TY - JOUR
T1 - Survival after segmentectomy and wedge resection in stage i non-small-cell lung cancer
AU - Smith, Cardinale B.
AU - Swanson, Scott J.
AU - Mhango, Grace
AU - Wisnivesky, Juan P.
N1 - Funding Information:
Supported in part by a research supplement to Promote Diversity in Health-Related Research Program Award Number [R01CA131348] from the National Cancer Institute.
Funding Information:
Disclosure: Dr. Wisnivesky is a member of the research board of Executive Health Exams International and has received lecture fees from Novartis Pharmaceutical and a research grant from GlaxoSmithKline. The other authors declare no conflict of interest.
PY - 2013/1
Y1 - 2013/1
N2 - INTRODUCTION: Although lobectomy is considered the standard surgical treatment for stage IA non-small-cell lung cancer (NSCLC), wedge resection or segmentectomy are frequently performed on patients who are not lobectomy candidates. The objective of this study was to compare survival among patients with stage IA NSCLC, who are undergoing these procedures. METHODS: Using the Surveillance, Epidemiology and End Results registry, we identified 3525 patients. We used logistic regression to determine propensity scores for patients undergoing segmentectomy, based on the patient's preoperative characteristics. Overall and lung cancer-specific survival of patients treated with wedge resection versus segmentectomy was compared after adjusting, stratifying, or matching patients based on propensity score. RESULTS: Overall, 704 patients (20%) underwent segmentectomy. Analyses, adjusting for propensity scores, showed that segmentectomy was associated with significant improvement in overall (hazard ratio: 0.80, 95% confidence interval: 0.69-0.93) and lung cancer-specific survival (hazard ratio: 0.72, 95% confidence interval: 0.59-0.88) compared with wedge resection. Similar results were obtained when stratifying and matching by propensity score and when limiting analysis to patients with tumors sized less than or equal to 2 cm, or aged 70 years or younger. CONCLUSIONS: These results suggest that segmentectomy should be the preferred technique for limited resection of patients with stage IA NSCLC. The study findings should be confirmed in prospective studies.
AB - INTRODUCTION: Although lobectomy is considered the standard surgical treatment for stage IA non-small-cell lung cancer (NSCLC), wedge resection or segmentectomy are frequently performed on patients who are not lobectomy candidates. The objective of this study was to compare survival among patients with stage IA NSCLC, who are undergoing these procedures. METHODS: Using the Surveillance, Epidemiology and End Results registry, we identified 3525 patients. We used logistic regression to determine propensity scores for patients undergoing segmentectomy, based on the patient's preoperative characteristics. Overall and lung cancer-specific survival of patients treated with wedge resection versus segmentectomy was compared after adjusting, stratifying, or matching patients based on propensity score. RESULTS: Overall, 704 patients (20%) underwent segmentectomy. Analyses, adjusting for propensity scores, showed that segmentectomy was associated with significant improvement in overall (hazard ratio: 0.80, 95% confidence interval: 0.69-0.93) and lung cancer-specific survival (hazard ratio: 0.72, 95% confidence interval: 0.59-0.88) compared with wedge resection. Similar results were obtained when stratifying and matching by propensity score and when limiting analysis to patients with tumors sized less than or equal to 2 cm, or aged 70 years or younger. CONCLUSIONS: These results suggest that segmentectomy should be the preferred technique for limited resection of patients with stage IA NSCLC. The study findings should be confirmed in prospective studies.
KW - Limited resection
KW - Non-small-cell lung cancer
KW - Segmentectomy
KW - Survival
KW - Wedge resection
UR - http://www.scopus.com/inward/record.url?scp=84871959073&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e31827451c4
DO - 10.1097/JTO.0b013e31827451c4
M3 - Article
C2 - 23164939
AN - SCOPUS:84871959073
SN - 1556-0864
VL - 8
SP - 73
EP - 78
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 1
ER -